title: ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a Neomorphic Transcription Network.
abstract: Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease with a relatively poorly understood pathogenesis. In this issue of Cancer Cell, Thirant and colleagues systematically examine unique transcriptional and functional effects of ETO2-GLIS2, an oncogenic fusion protein frequently encountered in AMKL, and elucidate a therapeutic vulnerability in this poor-prognosis leukemia.
authors.affiliation: Department of Cell Biology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.
authors.forename: Justin C
authors.initials: JC
authors.lastname: Wheat
authors.affiliation: Department of Cell Biology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA; Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA. Electronic address: ulrich.steidl@einstein.yu.edu.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Steidl
mesh_terms: D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D014157:Transcription Factors / Q000627:therapeutic use*
chemical_list: D015514:Oncogene Proteins, Fusion; D014157:Transcription Factors